Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

2 min read

Selexis to Participate at Several Upcoming Industry Conferences

Sep 5, 2017 9:27:19 AM

Geneva, Switzerland, 5 SEPTEMBER 2017Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, announced today its planned participation at upcoming industry conferences, as follows:

BioProcess International Conference
25 – 28 September 2017, Hynes Convention Center, Boston, USA
Selexis will attend the conference and exhibit along with KBI Biopharma.
For more information, please visit:

23rd Annual Partnering Conference BIO Europe
6 – 8 November 2017, CityCube Berlin, Berlin, Germany
Selexis will sponsor the conference and participate in the partnering program.
For more information, please visit:

 9th Annual PEGS Europe Protein & Engineering Summit
13 – 17 November 2017, EPIC SANA Lisboa Hotel, Lisbon, Portugal
Selexis Chief Scientific Officer Pierre-Alain Girod, PhD will present “Genome-Wide Signals Detection for Enhanced Cell Line Productivity and Stability” on Thursday, 16 November at 10:05 a.m. WET as part of the Expression track. Additionally, Selexis is a conference sponsor and exhibitor.
For more information, please visit:

About Selexis SA

Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly-specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 100 partners worldwide, 80+ drug products in clinical development and three commercial products utilizing Selexis-generated cell lines, the Company has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. More information is available at


- Web     
- LinkedIn
- Twitter 
- Facebook


Media Inquiries for Selexis

Mike Beyer
Sam Brown Inc.
+1 312-961-2502


Company Inquiries for Selexis

Robert Meister
Head, Corporate Communications
+1 602-953-1716

Topics: 2017